Catalyst Pharmaceuticals, Inc.
CPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -1.49 | 0.00 | 0.41 |
| FCF Yield | 1.34% | 2.69% | 2.04% | 2.83% |
| EV / EBITDA | 26.07 | 25.41 | 32.52 | 27.49 |
| Quality | ||||
| ROIC | 5.34% | 5.80% | 6.32% | 6.48% |
| Gross Margin | 84.73% | 79.56% | 87.33% | 84.74% |
| Cash Conversion Ratio | 0.61 | 1.37 | 1.06 | 1.27 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.40% | 22.62% | 27.74% | 31.92% |
| Free Cash Flow Growth | -54.49% | 18.70% | -15.18% | -2.51% |
| Safety | ||||
| Net Debt / EBITDA | -10.37 | -8.25 | -7.93 | -7.11 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.81 | 1.61 | 0.91 | 1.11 |
| Cash Conversion Cycle | 139.75 | 80.13 | 89.10 | 53.82 |